Oramed Pharmaceuticals, Inc

NASDAQ:ORMP   1:09:45 PM EDT
11.24
+0.73 (+6.95%)
Products

Oramed Reaches 25% Randomization In World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

Published: 03/16/2021 13:02 GMT
Oramed Pharmaceuticals, Inc (ORMP) - Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol.
Oramed Pharmaceuticals Inc - Ora-d-013-1 Study is Recruiting 675 Patients Through 75 Clinical Sites Throughout U.S.oramed Pharmaceuticals - Enrolled, Randomized 25% of 675 Patients Planned for Its Phase 3 Ora-d-013-1 Study of Its Oral Insulin Capsule Ormd-0801.